Medical Stocks Are Back — And This Time It's Different
For the better part of three years, healthcare sat in the shadows. While AI darlings and mega-cap tech hogged the headlines, pharma, medtech and managed care traded at valuations not seen in decades. Investors were spooked — drug pricing reform, reimbursement uncertainty…
For the better part of three years, healthcare sat in the shadows. While AI darlings and mega-cap tech hogged the headlines, pharma, medtech and managed care traded at valuations not seen in decades. Investors were spooked — drug pricing reform, reimbursement uncertainty, political noise. The sector became a graveyard for conviction. That's changing fast. The policy overhang that weighed on healthcare through most of 2025 is largely resolved. The first round of Medicare price negotiations is defined, tariff compromises are in place, and it turns out most large drugmakers can absorb the hit and still grow earnings. Markets hate uncertainty — not bad news. Once the uncertainty cleared, the re-rating was sharp. Global healthcare outperformed other sectors by more than 10% in Q4 2025, and the S&P 500 healthcare index has quietly taken over as a leadership group heading into 2026. Why now? The rotation makes sense when you look at what investors are running from versus what they're running to. Tech — particularly AI-linked names — is expensive. Not necessarily wrong, but priced for perfection in a macro environment that's softening. As growth slows and rate expectations stay elevated, the premium you pay for long-duration earnings becomes harder to justify. Healthcare offers something different: demand driven by ageing demographics and chronic disease, not economic cycles. Revenues are sticky, balance sheets are solid, and after years of underperformance, valuations are actually reasonable. Add a wave of M&A — Big Pharma is deploying cash to acquire biotech and medtech innovators — and you've got a sector with defensiveness, income, and discrete upside from takeover activity. Where the conviction is building Three areas are attracting the most attention right now. The GLP-1 obesity and diabetes story remains the biggest structural growth theme in global pharma. The class is projected to be a dominant driver of pharmaceutical sales well into the back half of this decade, and the leaders — think Novo Nordisk and Eli Lilly — have pipelines that extend well beyond weight loss into cardiovascular, kidney disease and metabolic health. This isn't a trade. It's a decade-long earnings story. Medtech and life-science tools are entering fresh product cycles while procedure volumes have fully normalised post-pandemic. After a long de-rating, select names now offer better growth and quality than many software peers — at a fraction of the multiple. That's a compelling setup. Managed care is the contrarian angle. Insurers and service providers got hammered on funding and reimbursement fears, but those with strong Medicare Advantage exposure have repriced plans for 2026 and reset expectations. For investors willing to look through the noise, the value is starting to look hard to ignore. The bigger picture Healthcare in 2026 isn't the defensive hiding spot it used to be. The narrative has shifted to defensive-growth — discounted valuations and robust cash flows on one side, genuine innovation in oncology, obesity and AI-accelerated drug discovery on the other. For portfolios that have ridden tech hard over the past two years, rotating some exposure into healthcare isn't capitulation — it's portfolio construction. Diversification with upside. A new leadership group that doesn't require the AI trade to keep working. The rotation has started. The question is whether you're ahead of it or behind it.
Read on MPC Markets Mosaic
